152 related articles for article (PubMed ID: 33085679)
1. Humoral responses to the measles, mumps and rubella vaccine are impaired in Leigh Syndrome French Canadian patients.
Fois A; Boucher-Lafleur AM; Thompson Legault J; Renaud C; Morin C; Des Rosiers C; Coderre L; Laprise C; Lesage S;
PLoS One; 2020; 15(10):e0239860. PubMed ID: 33085679
[TBL] [Abstract][Full Text] [Related]
2. Novel LRPPRC compound heterozygous mutation in a child with early-onset Leigh syndrome French-Canadian type: case report of an Italian patient.
Piro E; Serra G; Antona V; Giuffrè M; Giorgio E; Sirchia F; Schierz IAM; Brusco A; Corsello G
Ital J Pediatr; 2020 Sep; 46(1):140. PubMed ID: 32972427
[TBL] [Abstract][Full Text] [Related]
3. Expression signature of the Leigh syndrome French-Canadian type.
Bchetnia M; Tardif J; Morin C; Laprise C
Mol Genet Metab Rep; 2022 Mar; 30():100847. PubMed ID: 35242578
[TBL] [Abstract][Full Text] [Related]
4. mTORC1 is required for expression of LRPPRC and cytochrome-
Mukaneza Y; Cohen A; Rivard MÈ; Tardif J; Deschênes S; Ruiz M; ; Laprise C; Des Rosiers C; Coderre L
Am J Physiol Cell Physiol; 2019 Jul; 317(1):C58-C67. PubMed ID: 30995105
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
Nakayama T; Eda M; Hirano M; Goto W
Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
[TBL] [Abstract][Full Text] [Related]
7. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
8. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
9. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
10. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients.
Burelle Y; Bemeur C; Rivard ME; Thompson Legault J; Boucher G; ; Morin C; Coderre L; Des Rosiers C
PLoS One; 2015; 10(3):e0120767. PubMed ID: 25835550
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
13. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
14. Low-concentration methylene blue maintains energy production and strongly improves survival of Leigh syndrome French Canadian skin fibroblasts.
Legault J; Larouche PL; Côté I; Bouchard L; Pichette A; Robinson BH; Morin C
J Pharm Pharm Sci; 2011; 14(3):438-49. PubMed ID: 22202226
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
[TBL] [Abstract][Full Text] [Related]
17. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
19. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
20. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
